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We have selected an HXB2 variant which can replicate in the presence of a neutralizing human serum.
Sequencing of the gpl20 region of the env gene from the variant and parental viruses identified a single amino
acid substitution in the third conserved region of gpl20 at residue 375 (AGT-*AAT, Ser--Asn; designated 375
S/N). The escape mutant was found to be resistant to neutralization by soluble CD4 (sCD4) and four
monoclonal antibodies (MAbs), 39.13g, 1.5e, G13, and 448, binding to epitopes overlapping that of the CD4
binding site (CD4 b.s.). Introduction of the 375 S/N mutation into HXB2 by site-directed mutagenesis
confirmed that this mutation is responsible for the neutralization-resistant phenotype. Both sCD4 and three of
the CD4 b.s. MAbs (39.13g, 1.5e, and G13) demonstrated reduced binding to the native 375 S/N mutant gpl20.
The ability to select for an escape variant resistant to multiple independent CD4 b.s. MAbs by a human serum
confirms the reports that antibodies to the discontinuous CD4 b.s. are a major component of the group-specific
neutralizing activity in human sera.
Neutralizing antibody appears to be an important compo-
nent of the protective immune response against human
immunodeficiency virus type 1 (HIV-1) infection (1, 4-6).
Sera from many HIV-1-infected individuals are able to
neutralize a broad spectrum of virus isolates, indicating the
presence of conserved neutralization epitopes (28, 37). The
induction of antibodies with broad neutralizing capacity is a
primary goal of vaccine development strategies. Several
reports have suggested that HIV-1 neutralizing activity is
associated primarily with two regions of the gp120 envelope
glycoprotein: the third hypervariable loop (V3) (8, 10, 29)
and the CD4 binding site (CD4 b.s.) (11, 34). Generally,
antibodies specific for V3 arise early after HIV infection and
exhibit the ability to neutralize a limited number of HIV-1
isolates. However, a limited number of V3 monoclonal
antibodies (MAbs) recognize conserved features of the loop
and subsequently exhibit a broader neutralization profile (7,
10, 24). Later in the course of viral infection, antibodies
capable of neutralizing a wider range of HIV-1 isolates are
detectable (20, 28, 37). The appearance of such cross-
neutralizing activity coincides with the detection of antibod-
ies capable of blocking gp120-soluble CD4 (sCD4) interac-
tion (9, 11, 18, 34). A number of neutralizing MAbs derived
both from infected individuals (9, 12, 26, 30, 36) and from
recombinant gp120-immunized rats (3) which block gp120-
sCD4 binding have been identified, suggesting that such
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antibodies may play an important role in the cross-neutral-
izing response (21).
The selection and characterization of neutralization-resis-
tant escape mutants is one strategy for the identification of
amino acid residues critical for the binding of neutralizing
antibodies. We have selected escape variants which are
resistant to both V3 MAbs and sCD4 (13, 15). To define the
epitopes responsible for inducing cross-neutralizing antibod-
ies in human sera further, we selected an escape variant that
could replicate in the presence of a neutralizing human
serum. Characterization of the neutralization sensitivity of
the escape variant with a panel of MAbs mapping to the
second variable loop (V2), V3, and the CD4 b.s. demon-
strated that the variant was resistant to a number of MAbs
mapping to the CD4 b.s., suggesting that antibodies specific
for the CD4 b.s. in human sera are capable of cross-
neutralizing a nonhomologous HIV-1 isolate (HXB2) and
may be sufficient to select for neutralization-resistant escape
mutants.
MATERIALS AND METHODS
Virus propagation and neutralization assays. (i) Transfec-
tion of H9 cells and viral stock production. H9 cells were
washed twice in serum-free medium and resuspended at
106/ml in RPMI. Ten micrograms of HXB2 plasmid was
transfected into 2 x 106 H9 cells by the use of Lipofectin as
instructed by the manufacturer (GIBCO BRL, Gaithersburg,
Md.). The transfected H9 cultures were monitored for viral
infection by the detection of p24 antigen (as described
5216
RESISTANCE OF AN HIV-1 ESCAPE MUTANT TO NEUTRALIZATION 5217
below) and by the appearance of multinucleated cells. Once
the cells were producing virus (days 6 to 7 posttransfection),
stocks of extracellular virus were made by mixing the
infected cells with uninfected H9 cells in a 1:4 ratio. Forty-
eight hours after the cocultivation, the supernatant was
collected, aliquoted, and stored under liquid N2. Infectivity
determinations were made by performing 10-fold serial dilu-
tions of virus (50 pI) and incubation with 100 pI of C8166
cells at 2 x 105 cells per ml in microtiter plates at 37°C for 7
days. Plates were scored for the presence of p24 antigen, and
the 50% tissue culture infective dose (TCID50) values were
determined by the Karber formula.
(ii) Neutralization assays. HIV (103 TCID50) in a volume of
40 ptl was incubated with 10 RI of a dilution of antibody,
serum, or sCD4 under test at 37°C for 1 h. The virus-
antibody or virus-sCD4 mixture was then incubated with 100
pI of C8166 cells at a concentration of 2 x 105 cells per ml
per well in a microtiter plate in triplicate. Five days postin-
fection, the wells were scored for the presence of syncytia,
and the extracellular supernatant was collected from the
wells by centrifugation, inactivated with 1% Empigen, and
assayed for soluble p24 antigen as described previously (17).
The lowest concentration of antibody or sCD4 resulting
either in a complete blocking of syncytium formation or in a
>90% reduction in p24 antigen production was defined as the
reciprocal neutralization titer.
(iii) Comparative neutralization of variant and wt virus by
human sera. Human serum neutralization titers were ob-
tained for both variant and wild-type (wt) viruses. The
differences in the titers were compared by using a two-tail
nonparametric test (Wilcoxon's rank sum) (see Fig. 7).
MAbs and human sera. The following antibodies were
used for neutralization studies and/or envelope binding stud-
ies: rat MAbs 10/54, 10/36e, and 11/85b, specific for amino
acids 311 to 321 of the HXB10 V3 loop (14); rat MAb 41.1,
recognizing a conformation-dependent epitope within the V3
loop (14); rat MAb 10/76b, mapping to a linear epitope in the
V2 loop (17a); 38.1a, specific for amino acids 425 to 441,
involved in CD4 binding (3); 39.13g, a rat MAb specific for
an epitope overlapping the CD4 b.s. (3, 19); and human
MAbs 588, 559, 448, 728, 654, 729 (12, 19), 1.5e, 2.1h (9, 35),
and G13 (30), binding to closely related epitopes overlapping
the CD4 b.s.; and murine MAb L120, specific for CD4
(Medical Research Council [MRC] AIDS Directed Pro-
gramme [ADP] Repository).
Sera were collected from 21 healthy CDC stage II and III
seropositive males attending a sexually transmitted disease
clinic as part of a longitudinal study of the natural history of
HIV-1 infection (2). These individuals had not received
antiretroviral therapy at the time of sampling.
Antibody and sCD4 binding to detergent-solubilized viral gp
120. Virus-containing supernatants were inactivated with 1%
Nonidet P-40 (NP-40), which does not irreversibly denature
gpl20/160 (23). The concentrations of gpl20 present in the
preparations were determined by a twin-site enzyme-linked
immunosorbent assay (ELISA) as previously described (22,
23), using recombinant gpl20 (rgpl2O; BH10 clone), ex-
pressed in and purified from CHO cells, as a reference
standard. Briefly, detergent-solubilized gpl20 from wt, vari-
ant, and 375 S/N (see Results for definition) site-directed
mutant viral stocks was allowed to bind to the solid phase via
the capture antibody D7324 (anti-C terminus; Aalto-Biore-
agents, Dublin, Ireland) at an input concentration of 50
ng/ml. The abilities of MAbs and sCD4 to bind to the
captured gpl20 were assessed by using methods previously
published (13, 19). In each case, the result is expressed as a
ratio of the optical density of the mutant protein to that of the
wt protein and is termed the relative binding index.
MAb cross-competition analysis for rgpl2O binding. The
human CD4 b.s. MAbs and three control rat MAbs binding
to the V2, V3, and fourth conserved (C4) regions of gpl20
were tested for the ability to compete with iodinated prepa-
rations of MAb 39.13g for binding to D7324-bound rgpl20.
The unlabeled MAbs, at a concentration sufficient to satu-
rate the gpl20 (5.0 ,ug/ml), were mixed with an equal volume
of 39.13g, at a concentration resulting in half-maximal bind-
ing (0.16 ,ug/ml), and the mixture was incubated with gpl20
for 1 h. The amount of 39.13g bound to gpl20 in the presence
or absence of the test MAbs was determined.
Cell surface MAb and sCD4 binding. Infected H9 cells
were washed twice in complete phosphate-buffered saline
(PBS)-1% fetal calf serum-0.05% sodium azide (WB), resus-
pended at a concentration of 107 cells per ml in WB, and
chilled on ice. MAbs or sCD4 were diluted in WB, and 100 ,ul
was mixed with 100 ,u of cells (106 cells) and incubated in a
V-bottom microtiter plate for 30 min. Cells were washed
with WB by centrifugation, and the bound MAb was de-
tected with a 1/40 dilution of fluorescein isothiocyanate-
conjugated anti-rat immunoglobulin G (IgG) or anti-human
IgG (SeraLabs; Crawley, Sussex, United Kingdom) in WB.
Bound sCD4 was detected with CD4-specific MAb L120
(MRC ADP Repository) and fluorescein isothiocyanate-con-
jugated anti-mouse IgG. After a 30-min incubation on ice
with the conjugate, the cells were washed three times with
WB and inactivated by resuspension in 500 RIu of 1%
paraformaldehyde in PBS at 4°C overnight. Cells were
analyzed on a FACStar, using Lysis software (Becton Dick-
inson). The results shown are the mean fluorescence inten-
sities obtained for one experiment. However, all experi-
ments were repeated three times.
Cassette vector construction and site-directed mutagenesis.
The HXB2 insert of plasmid pHXB2gpt was transferred into
a vector lacking XbaI sites by ligation into the NheI site of a
pSPTBM20 vector (Boehringer Mannheim), from which the
polylinker had previously been excised by double digestion
with SmaI and EcoRV and self-ligation. A derivative, MCS,
was constructed by introducing a silent site-directed muta-
tion in the gpl60 gene to generate an XbaI site and two
nonsilent changes in the nonfunctional vpu gene to generate
a NotI site. Virus recovered upon transfection of the modi-
fied plasmid was able to infect H9 cells with the same
infection kinetics as the parental HXB2. Infection of 106 H9
cells with viral doses of HXB2 and HXB2-MCS containing
200 pg of virion p24 resulted in soluble p24 production at 4,
6, 8, and 10 days postinfection of 7.6, 120.0, 390.0, and 510.0
ng/ml and 5.0, 185.0, 425.0, and 525.0 ng/ml, respectively. A
deleted form of MCS made by double digestion of the
construct with NheI and MamI followed by Klenow fill-in of
the NheI end and self-ligation. This digestion excised a
295-bp piece of the envelope gene including the V4, C4, and
V5 domains (see Fig. 3), and the plasmid was shown to be
noninfectious (data not shown).
Generation and cloning of wild-type and variant gpl20
molecules. Single molecules of gpl20 were amplified by a
limit dilution method (31) using nested primers specific for
the vpu region (sense) and for the gp4l molecule (antisense).
Initial amplification was performed in a volume of 20 ,u with
primers TCA TCA AGT TTC TCT AC/TC AAA GC (5'
sense, outer; positions 5568 to 5590 (23a) and TCC CAC
TCC ATC CAG GTC (3' antisense, outer; positions 7664 to
7647) (23a), using 30 cycles of polymerase chain reaction
(PCR) amplification (94°C, 40 s; 50°C, 35 s; 72°C, 210 s) with
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TABLE 1. Neutralization sensitivities of wt and variant viruses
Neutralization titer
Ligand Epitope (,ug/ml or reciprocal dilutiona)
wt Variant
41.1 V3 0.4 + 0.05 0.5 ± 0.06
10/54 V3 9.4 ± 1.8 8.4 ± 1.6
10/36e V3 1.2 + 0.4 0.8 ± 0.3
11/85b V3 1.3 + 0.5 1.1 ± 0.3
10/76b V2 0.9 ± 0.2 1.2 ± 0.3
39.13g CD4 b.s. 5.4 ± 0.8 NRb
sCD4 2.5 ± 0.4 NR
QC5 (selecting serum) 1/640 1/150
a Reciprocal dilution is given for QC5.
b NR, 90% reduction in p24 antigen production was not achieved for the
variant virus with either 39.13g or sCD4. At 20 ,ug/ml, the variant was
neutralized by 10 and 53% by 39.13g and sCD4, respectively.
16 ng of each primer, 200 ,uM each deoxynucleoside triphos-
phate (dNTP), 50 ,uM TMAC, 1 x PFU of polymerase buffer
3, and 0.5 U of polymerase (Stratagene). To prevent degra-
dation, the first-round product was frozen immediately upon
completion of the reaction. One microliter of this first-round
product was transferred to a second tube containing a
volume of 100 ,ul with primers GTA GCA TTA GCG GCC
GCA ATA ATA ATA GCA ATA G (5' sense, NotI inner;
positions 5635 to 5668) (23a) and GTT CTA GAG ATT TAT
TAC TCC (3' antisense, XbaI inner; positions 7631 to 7611)
(23a), using 25 cycles of amplification (94°C, 35 s; 55°C, 25 s;
72°C, 150 s) with 80 ng of each primer, 200 ,uM each dNTP,
50 ,uM TMAC, lx PFU polymerase buffer 3, and 2.5 U of
PFU polymerase. Ten microliters of the PCR product was
visualized on an agarose gel, and the remainder was purified
by a Gene-Clean (Bio 101, La Jolla Calif.) procedure. After
digestion with NotI and XbaI (Promega Biotec), and PCR
product was ligated into NotI-XbaI-digested pHXB2-
MCSAenv and cloned into Escherichia coli SURE (Strata-
gene). Colonies were screened for full-length clones by PCR
and full-length clones were sequenced to confirm the insert
genotype.
Site-directed mutation and cloning of gp120 molecules.
Site-directed mutagenesis of the HXB2 envelope was per-
formed by a modification of the method of Wolfs et al. (38),
using PFU polymerase in place of Taq polymerase. Two
20-pl PCR reactions were set up as described above, with 25
ng ofpHXB2gpt as the template, using either the 3' antisense
XbaI primer and a sense primer encoding the desired 375
mutation or the 5' sense NotI inner primer and a second,
antisense, 375 primer. The use of this relatively large amount
of template DNA allowed us to reduce the number of cycles
performed in the PCR and hence the frequency of poly-
merase-introduced error; the PCR was run for 10 cycles,
using the temperature profile described above for the second
round. The PCR products were gel purified by a Gene-Clean
procedure, and the two products were pooled into a 100-,ul
PCR mix containing the 5' sense Notl inner primer and the 3'
antisense XbaI primer; this mixture was reamplified for a
further 10 cycles, using the same temperature profile as
before. The final, full-length product was separated from the
two shorter products on a 1.5% agarose gel, purified, cloned,
and screened as described above. The presence of the
desired change was verified by sequencing.
RESULTS
Selection procedure. Experiments were designed to moni-
tor the kinetics of the appearance of HIV-1 escape mutants
propagated in the presence of a HIV-1-positive human
serum. The serum chosen, QC5 (16), neutralized HXB2 at a
serum dilution of 1/640 and contained antibodies capable of
blocking the gpl2O-sCD4 interaction (data not shown). Virus
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FIG. 1. Binding of MAbs and sCD4 to wt and variant gp120/160.
Increasing concentrations of MAbs 41.1, mapping to the V3 loop
(A), 39.13g, mapping to a discontinuous epitope overlapping that of
the CD4 b.s. (B), and sCD4 (C) were analyzed for the ability to bind
to NP-40-solubilized viral gp120 from wt and variant viral stocks.
OD, optical density.
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(C)
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obtained by transfection of the HIV-1 molecular clone
HXB2 into C8166 cells was allowed to infect the H9 cell line
at multiplicities of infection of 0.1 and 0.01 for 2 h at 37°C.
After viral adsorption, unbound virus was removed by
washing and the cells were cultured in the presence of either
a seronegative human serum (AB') or serum QC5 at final
dilutions of 1/40, 1/80, 1/160, and 1/320. Cultures were fed
biweekly with the human sera and were monitored for both
cytopathic effect and p24 antigen production.
After 2 weeks, virus was recovered as cell-free supema-
tant from the cultures containing the lowest serum dilutions
(1/160 and 1/320). After 4 weeks of propagation, viral antigen
(p24) was detected in the culture containing QC5 at a 1/80
dilution. Over a 7-week period, no evidence for viral repli-
cation was observed in the highest concentration of selecting
serum (1/40). The virus-containing supernatants were tested
for sensitivity to neutralization by the selecting serum. Virus
rescued from the cultures containing QC5 at a 1/80 dilution
was partially resistant to neutralization by QC5 (Table 1).
However, virus obtained in the presence of the two lowest
concentrations of QC5 was not resistant to neutralization by
the selecting serum (data not shown).
This partially resistant virus was tested for its sensitivity
to neutralization by sCD4 and a number of rat gpl20 MAbs:
39.13g, binding to a discontinuous epitope overlapping with
that of CD4 and capable of blocking the gpl2O-sCD4 inter-
action (3, 19); 10/54, 10/36e, 11/85b, and 41.1, binding to
epitopes in the V3 loop (14); and 10/76b, binding to a linear
epitope in the V2 loop (17a). The variant was resistant to
neutralization both by MAb 39.13g and by sCD4 (Table 1).
However, the variant was as susceptible as the parental
virus to neutralization by all of the V2 and V3 MAbs (Table
1).
MAb recognition of variant gp120. We measured the ability
of sCD4 and MAbs 39.13g and 41.1 to bind to nonionic
detergent (NP-40)-solubilized wt and variant viral gpl20 (at
an input concentration of 50 ng/ml). The V3 MAb 41.1 bound
to the variant and wt gpl20 with comparable affinities (Fig.
IA). In contrast, MAb 39.13 g showed a reduced binding
affinity (10.6-fold) for the variant gpl20 (Fig. 1B), in agree-
ment with the reduced ability of the MAb to neutralize the
variant. However, sCD4 bound to the variant gpl20 with an
affinity comparable to that of the wt (Fig. 1C), which was
unexpected given the reduced ability of sCD4 to neutralize
the variant (Table 1). We have previously reported differ-
ences in the abilities of both MAbs (14) and sCD4 (22) to bind
to native virion gpl20 and detergent-solubilized gpl20. We
therefore monitored the binding of MAbs and sCD4 to native
envelope expressed on the surface of infected cells. sCD4
induces gpl20 shedding from the cell surface at 37°C (23);
therefore, all ligand titration curves were performed at 4°C to
prevent this. In agreement with the ELISA data, MAb
39.13g (at a saturating concentration) bound less well to
variant-infected H9 cells than to wt-infected cells, resulting
in a mean fluorescence intensity of 50.2 versus 71.5, respec-
tively (Fig. 2B). A saturating concentration of sCD4 (10
,ug/ml) bound equivalently to wt-infected and variant-in-
fected cells, with mean fluorescence intensities of 170 and
176, respectively (Fig. 2C). However, concentrations of
sCD4 resulting in half-maximal binding (1.0 ,ug/ml) demon-
strated a twofold reduction in binding to variant-infected
cells compared with wt-infected cells, suggesting that the
native variant envelope had a reduced binding affinity for
sCD4 (Fig.2C). V3 MAb 41.1 bound to wt-infected and
variant-infected cells with similar affinities, suggesting that
the level of gpl20 cell surface expression was comparable in
1 50
_4v4 100
50
0
80
60
LL4
40
20
0
-A
200
1 50
100
0 0.3 1 3 10 30
sCD4 uglml
FIG. 2. Binding of MAbs and sCD4 to wt- and variant-infected
cells. Increasing concentrations of MAbs 41.1, mapping to the V3
loop (A), 39.13g, mapping to a discontinuous epitope overlapping
that of the CD4 b.s. (B), and sCD4 (C) were analyzed for the ability
to bind to wt- and variant-infected H9 cells at 4'C. The mean
fluorescence intensity (F.I.) from an individual experiment is
shown.
the infected cultures (Fig. 2A). The reduced binding of sCD4
to the variant-infected cells compared with the wt-infected
cells was not attributable to differential sCD4-induced gpl20
shedding, since the concentration of extracellular soluble
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FIG. 3. pHXB2-MCS construct. The diagram shows the locations of the major genes and restriction sites used in this study. The Aenv
construct is shown by the circle in which the NheI and MamI sites used for the deletion are noted. prot, protease; rt, reverse transcriptase;
int, integrase.
gpl20 was found to be identical for the wt- and variant-
infected H9 cells (data not shown).
Sequence analysis of variant and site-directed mutagenesis.
We have previously identified gp120 residues 113, 117, 256,
257, 262, 368, 370, and 421 as being involved in the binding
of MAb 39.13g (19). These regions overlap with those
reported to be important for sCD4 binding (25). We therefore
sequenced the gp120 of both the variant and wt viruses and
identified a single amino acid substitution at codon 375
(AGT->AAT, Ser--Asn; designated 375 S/N). To confirm
that the gpl20 mutation at 375 is responsible for the resis-
tance of the variant to 39.13g neutralization, we cloned both
the wt and variant gpl20 genes into a viable HIV-1 cassette
vector, pHXB2-MCS (Fig. 3). In addition, we generated a
synthetic mutation at codon 375 by site-directed mutagenesis
and also cloned this mutated gpl20 into pHXB2-MCS. The
viral stocks recovered from transfection with several clones,
named HXB2-wt, HXB2-var, and HXB2-375 S/N, respec-
tively, were tested both for their sensitivities to neutraliza-
tion by the original selecting serum QC5 and a range of
neutralizing MAbs and for their abilities to bind MAbs.
HXB2-var (clone 23) and HXB2-375 S/N (clone 9) were both
resistant to neutralization by QC5 and 39.13g but remained
sensitive to neutralization by MAbs specific for the V2 and
V3 domains (Table 2), confirming that the mutation at
residue 375 is responsible for the neutralization-resistant
phenotype. Additional clones of HXB2-var and HXB2-375
S/N demonstrated similar neutralization profiles (data not
shown).
Neutralization and MAb binding to the 375 S/N site-directed
mutant. There are a number of neutralizing human MAbs
which block gpl2O-sCD4 binding and which have similar
binding properties to a panel of site-directed gpl20 mutants
as 39.13g (19, 30, 33, 35). All of the human MAbs tested were
able to cross-compete with 39.13g for gpl20 binding (Fig. 4),
suggesting that the epitopes recognized by the human MAbs
may overlap that of 39.13g. We therefore investigated the
sensitivity of HXB2-375 S/N to neutralization by a panel of
nine human MAbs. Both HXB2-var and HXB2-375 S/N were
as sensitive as HXB2-wt to neutralization by the CD4 b.s.
MAbs 559, 728, 654, 729, 588 (12), and 2.1h (35) but were
resistant to neutralization by three additional MAbs, 1.5e
(9), G13 (30), and 448 (12) (Table 2). MAbs 1.5e and G13
showed reduced binding indices for both the cloned variant
and the 375 S/N site-directed mutant viral gp120, both by
ELISA (Fig. 5) and by cell surface fluorescence-activated
cell-sorting (FACS) analysis (data not shown), in good
agreement with the observed resistance to neutralization.
However, MAb 448, which demonstrated a reduced ability
TABLE 2. Neutralization sensitivities of HXB2-wt, HXB2-var,
and HXB2-375 S/Ne
% Neutralization
Ligand Epitope
HXB2-wt HXB2-var HXB2-375 S/N
559 CD4 b.s. 83 14 43 9 54± 10
448 CD4 b.s. 72 6 2 0.5 4 0.3
728 CD4 b.s. 80 17 59 16 68± 13
654 CD4 b.s. 84 18 61 13 78 18
729 CD4 b.s. 44 9 54 8 67± 11
588 CD4 b.s. 85 14 87 19 93 20
G13 CD4 b.s. 95 8 4 0.3 3 0.2
1.5e CD4 b.s. 56 ± 7 3 ± 0.2 4 ± 0.3
2.1h CD4 b.s. 67 9 56 7 62 10
39.13g CD4 b.s. 94 ± 14 10 ± 0.9 8 ± 0.7
11/85b V3 96 6 89 14 92 15
41.1 V3 98 7 96 6 98 6
10/76b V2 96 8 94 10 97 9
sCD4 94 7 37 ± 2 28 3
QC5 (human serum) 94 ± 8 43 ± 6 38 ± 4
a All antibodies and sCD4 were tested at a final concentration of 10.0 pLg/ml
with the exceptions of 559 (0.86 ,ug/ml), 728 (2.20 ,ug/ml), 654 (5.30 ,ug/ml), and
729 (1.94 pg/ml), which were tested at the highest concentrations feasible (in
parentheses). The selecting serum QC5 was tested at a final dilution of 1/100.
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FIG. 4. Cross-competition analysis for MAb 39.13g binding to rgpl20. MAbs (at a saturating concentration of 5.0 jLg/ml) mapping to a
linear V2 epitope (10/76b), to a linear C4 epitope (38.1a), to a linear V3 epitope (10/54), and to epitopes overlapping the CD4 b.s. (588, 448,
728, 654, 729, 559, 1.5e, 2.1h, and G13) were tested for their ability to compete with iodinated 39.13g for binding to rgpl20. The results
represent means of triplicate wells and are from one experiment, but similar results were obtained in two separate experiments.
to neutralize both the variant and 375 S/N mutant viruses
(Table 2), bound to detergent-solubilized gp120/160 with
binding indices of 0.81 and 0.82, respectively. Furthermore,
no detectable difference in the ability of MAb 448 to bind to
the surface of wt- or variant-infected H9 cells was observed
by FACS staining (data not shown). The remaining six
human MAbs and three control MAbs, mapping to V2, V3,
and C4, bound to the variant and 375 S/N site-directed
mutant antigens with binding indices ranging from 0.8 to 1.20
(Fig. 5).
Since MAbs 39.13g, 1.5e, and G13 still bind to HXB2-375
S/N, though with reduced binding indices, we investigated
the mechanism of neutralization resistance. Since all of these
MAbs block in vitro the gpl20-sCD4 interaction, they pre-
sumably neutralize by preventing virion attachment to CD4.
We therefore tested the ability of a number of CD4 b.s.
MAbs, together with control MAbs specific for the V2, V3,
and C4 regions of gpl20, to block sCD4 binding to NP-40-
solubilized HXB2-wt, HXB2-var, and HXB2-375 S/N viral
gpl20 by ELISA. MAbs 39.13g, 1.5e, and G13 (5 ,ug/ml)
blocked sCD4 binding to HXB2-wt gpl20 by 82, 83, and
79%, to HXB2-375 S/N mutant by 27, 29, and 20, and to
HXB2-var by 24, 22, and 26%, respectively (Fig. 6). Since
the gpl20-sCD4 binding assay was performed with NP-40-
solubilized viral g120, it is not surprising that MAb 448
inhibited sCD4 binding to wt and variant gpl20 equivalently
(Fig. 6).
Since the 375 S/N mutation was originally selected for by
an HIV-1-positive human serum, we investigated the sensi-
tivity of the variant to neutralization by a panel of sera from
HIV-1-infected individuals classified in CDC stages II and
III (Fig. 7). Eleven of 21 sera showed a reduced neutraliza-
tion titer for the variant, with a median neutralization titer of
1/20, compared with 1/40 for HXB2-wt (P = 0.0092, two-
tailed Wilcoxon rank test).
DISCUSSION
We have selected an HIV-1 variant which can replicate in
the presence of a neutralizing human serum (Table 1).
Sequencing of the gpl20 genes from both the variant and the
wt virus identified a single amino acid change in the C3
region of gpl20, at residue 375 from Ser to Asn. Character-
ization of this mutation, both as a cloned variant gpl20
(HXB2-var) and as a site-directed mutant (HXB2-375 S/N),
demonstrated that the mutation conferred resistance to
neutralization by MAbs 39.13g (3), 1.5e (9), G13 (30), and
448 (12), binding to epitopes overlapping the CD4 b.s., and
by sCD4 (Table 2). In agreement with the reduced sensitivity
to neutralization, MAbs 39.13g, 1.5e, and G13 demonstrated
reduced binding to NP-40-solubilized HXB2-var and HXB2-
375 S/N viral gpl20 with binding indices of 0.48, 0.42, and
0.46 and of 0.42, 0.45, and 0.43, respectively (Fig. 5).
However, MAb 448 bound to the cloned variant and mutant
proteins with binding indices of 0.81 and 0.82. The relatively
modest change in binding index observed with both MAb 448
and sCD4 for the variant and the 375 S/N mutant, despite the
reduced neutralization sensitivity, suggests that studying the
binding of ligands to detergent-solubilized viral antigen may
not accurately predict the behavior of such ligands with the
native protein. We have previously reported a difference in
the ability of sCD4 to bind to soluble gpl20 and native intact
virion gpl20 (22), suggesting that the tertiary and/or quarter-
nary structure of native oligomeric gpl20/41 influences the
binding affinity of sCD4.
MAbs 39.13g, 1.5e, and G13 were less efficient at blocking
sCD4 binding to solubilized HXB2-var and HXB2-375 S/N
viral gpl20 than to HXB2-wt gpl20 (Fig. 6), suggesting that
the efficiency of neutralization by CD4 b.s. antibodies may
be governed by the affinity of the antibody for the envelope
glycoprotein. By using a panel of site-directed gpl20 mu-
tants, the epitopes recognized by the CD4 b.s. MAbs, with
the exception of 728 and 654, have been mapped (19, 30, 33,
35) to five discontinuous regions including amino acids 113 to
117 in Cl, 256 to 262 in C2, 368 to 370 in C3, 421 to 427 in C4,
457 in C4, and 475 to 477 in C5. The regions of gpl20
recognized by the MAbs differ slightly, but most depend on
a core of amino acids including Asp-368, Glu-370, Thr-257,
and Lys-421. There is no obvious pattern from the mapping
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FIG. 5. Binding of MAbs to wt, variant, and 375 S/N mutant gp120/160. MAbs (at a saturating concentration of 5.0 ,ug/ml) mapping to a
linear V2 epitope (10/76b), to a linear C4 epitope (38.la), to a linear V3 epitope (10/54), and to epitopes overlapping the CD4 b.s. (39.13g, 588,
448, 728, 654, 729, 559, 1.5e, 2.1h, and G13) were compared for the ability to bind to NP-40-solubilized gp120/160 from HXB2-375 S/N (A)
and HXB2-var (B) with HXB2-wt. The results are expressed as the ratio of MAb (optical density) bound to the variant or site-directed mutant
relative to the wt and are termed the relative binding index.
data to explain why MAbs 39.13g, 1.5e, G13, and 448 are
unable to neutralize the escape mutant whereas MAbs 559,
728, 654, 729, 588, and 2.1h neutralize the mutant as well as
the wt virus. Amino acids from four of these regions (Thr-
257, Asp-368, Glu-370, Trp-427, and Asp-457) have been
implicated in CD4 binding (25). Thus, a number of amino
acid residue changes significantly affect MAb binding with-
out affecting sCD4 recognition, suggesting that viral escape
from antibody neutralization may occur without affecting the
ability of the virus to bind to its receptor (19). However, the
375 S/N variant was also resistant to neutralization by sCD4
(Tables 1 and 2). sCD4 demonstrated a reduced binding
affinity for native envelope but not for detergent-solubilized
gpl20 (Fig. 1 and 2). Olshevsky and colleagues (25) reported
that mutation of residues 368 and 370 abrogated sCD4
binding in the presence or absence of nonionic detergents;
however, residue 375 was not studied by these authors.
Reitz and colleagues (27) reported on a serum-selected
escape mutant which had a single change in gp4l at residue
582 (Ala-Thr, or A/T), which exhibited a decreased suscep-
tibility to neutralization by approximately one-third of hu-
man sera tested. Since antibodies to linear epitopes encom-
passing residue 582 were not neutralizing, Wilson and
colleagues (37) hypothesized that a neutralization epitope(s)
may be affected by the change in gp4l. More recently, we
(12b) and others (31a) have reported that the 582 A/T mutant
is insensitive to neutralization by a number of CD4 b.s.
MAbs, including F105 (26), 1.5e (9), and 39.13g (3). The 582
A/T mutant appears to bind the MAbs with an affinity
equivalent to that of the wt. This is in contrast to the 375 S/N
mutant, which has a reduced affinity for MAbs 39.13g, G13,
and 1.5e (Fig. 5). This finding suggests that escape from CD4
b.s. MAbs may occur by one of at least two mechanisms,
either by a mutation which directly reduces the affinity of the
MAb for gpl20 (Fig. 5) or by a mutation which indirectly
affects events after MAb binding. Alternatively, a small
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FIG. 6. Abilities of MAbs to inhibit the interaction of HXB2-wt, HXB2-var, and HXB2-375 S/N gpl20/160 with sCD4. MAbs (at a
saturating concentration of 5.0 p.g/ml) mapping to a linear V2 epitope (10/76b), to a linear C4 epitope (38.1a), to a linear V3 epitope (10/54),
and to epitopes overlapping the CD4 b.s. (39.13g, 588, 448, 1.5e, 2.1h, and G13) were tested for the ability to inhibit sCD4 (1.0 1Lg/ml) binding
to NP-40-solubilized gpl20/160 (50 ng/ml) from HXB2-wt, HXB2-var, and HXB2-375 S/N viral stocks.
reduction in the affinity of mutant 582 A/T for the MAbs or
of mutant 375 S/N for MLAb 448, not measurable by current
assays, may be sufficient to account for the differential
neutralization observed (32).
The 375 S/N mutant replicates in CD4+ cells as efficiently
as the wt does, as assessed by measuring the infectivity-to-
particle ratio (TCID50 virion p24) (data not shown) (17). This
finding is in agreement with the ability of sCD4 and sCD4-
IgG neutralization-resistant variants to replicate as well as
the neutralization-sensitive parental virus does (12a, 13).
This observation is consistent with reports that replication-
competent viruses can exhibit a wide range of CD4-binding
affinities and may be explained by the greater cooperativity
A1
.
of envelope-receptor interactions during virus-cell or cell-
cell fusion compared with the interaction of soluble CD4 and
gp120 (32).
The ability of a polyclonal serum to select for a mutation
in C3 which affects the sensitivity to neutralization both by
sCD4 and CD4 b.s. MAbs confirms that antibodies binding
to the CD4 b.s. contribute to the group-specific neutraliza-
tion response (21, 32). However, the 375 S/N mutant was
only partially resistant to 11 of 21 human sera tested (Fig. 7),
suggesting that either the cross-neutralizing activity may be
attributed to an epitope(s) in addition to the CD4 b.s. or the
CD4 b.s. induces a complex antibody response involving
many discontinuous overlapping epitopes. The latter sugges-
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FIG. 7. Sensitivities of wt and variant viruses to neutralization by sera from HIV-1-infected individuals. Reciprocal neutralization titers
of 21 human sera for wt and variant viruses are shown. Average titers (horizontal lines) were 1/40 for the the wt and 1/20 for the variant
(Wilcoxon rank test, P = 0.009).
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tion is supported by the observation that three of nine human
MAbs mapping to the CD4 b.s. failed to neutralize the 375
S/N mutant (Table 2). The subdivision of this panel of CD4
b.s. MAbs into groups based upon their ability to neutralize
375 S/N suggests that current methods of epitope mapping,
recognition of synthetic or site-directed gp120 mutants, and
cross-competition assays are insufficiently sensitive to define
MAb epitopes completely. These data suggest that single
amino acid changes resulting in resistance to one selecting
agent may not lead to complete resistance to a polyclonal
mixture of antibodies present in a heterologous serum.
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